ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein (Q39450845)

12 September 2017

title

ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein (English)

1 reference

12 September 2017

0 references

Guan Wang

1

1 reference

12 September 2017

Yao Zhan

series ordinal

2

1 reference

12 September 2017

Haiqing Wang

series ordinal

3

1 reference

12 September 2017

Wenhua Li

series ordinal

4

1 reference

12 September 2017

publication date

29 October 2011

1 reference

Cancer Chemotherapy and Pharmacology

12 September 2017

published in

1 reference

12 September 2017

volume

69

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

799-805

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-011-1763-0

12 September 2017

exact match

0 references

cites work

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

The Bcl-2 apoptotic switch in cancer development and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Bcl-2 functions in an antioxidant pathway to prevent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Mitochondrial control of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Mechanisms of caspase activation and inhibition during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Expression of fas ligand in human hepatoma cell lines: role of hepatitis-B virus X (HBX) in induction of Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

TRAIL and apoptosis induction by TNF-family death receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

Hepatitis B virus X protein induces expression of Fas ligand gene through enhancing transcriptional activity of early growth response factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1763-0

10.1007/S00280-011-1763-0

21 January 2018

Identifiers

DOI

1 reference

release_oxdc66hhfbexzllt6j4u6wdwpy

12 September 2017

Fatcat ID

0 references

1 reference